Jump to Main Content

FDA Alerts

FDA Approves Ravulizumab-cwvz for Paroxysmal Nocturnal Hemoglobinuria

The Food and Drug Administration approved ravulizumab-cwvz (ULTOMIRIS, Alexion Pharmaceuticals, Inc.) for adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Citations